Answers are grounded in this paper and cite their sources.
Background Neuroinflammation and peripheral adaptive immune dysregulation have been implicated in Alzheimer’s disease (AD), but whether peripheral immune alterations are detectable at the earliest biomarker-defined stages remains unclear. Most immunophenotyping studies enrolled patients with clinically manifest dementia without biomarker confirmation. Methods We conducted a prospective, observational, single-centre study in consecutive adults with normal cognition or mild cognitive impairment (MMSE >22; CDR 0–0.5). Participants were classified by CSF and blood biomarkers into biomarker-defined AD, other dementias (OD), and non-degenerative cognitive complaints (NDC). Peripheral blood surface-marker immunophenotyping by multiparametric flow cytometry characterised B-cell and T-cell compartments, including regulatory, conventional helper, follicular helper, and double-negative T-cell subsets. Groups were compared using Benjamini-Hochberg-adjusted parametric and non-parametric tests. Exploratory analyses included principal component analysis, permutational multivariate analysis of variance (PERMANOVA), correlations between immune subsets and AD biomarkers, and a logistic regression model discriminating AD from NDC, evaluated by ROC analysis. Results Seventy-nine participants were included (AD n=43, OD n=18, NDC n=18). No significant differences were detected in any lymphocyte population between biomarker-defined AD and NDC after multiple-testing correction. The clearest, albeit modest, multivariate separation was between AD and OD, driven by nominally higher frequencies of Th17-like regulatory T cells and Th9-like cells in OD that did not survive correction, except for Th17-like regulatory T cells in the age- and sex-adjusted AD-versus-OD comparison. Double-negative γδ T cells were numerically, but not significantly, lower in AD than in NDC, and an exploratory logistic model including double-negative T-cell subsets achieved moderate discrimination (AUC 0.743) without external validation. Correlations between immune subsets and AD biomarkers were weak; the most apparent was between Th17-like regulatory T cells and CSF neurofilament light chain, not amyloid-β or tau. Conclusions No significant differences in peripheral adaptive immune profiles were detected between biomarker-defined early AD and NDC, suggesting that overt peripheral immune activation is not yet established at the earliest stages of the Alzheimer’s continuum. The exploratory differences between AD and OD, involving Th17-like regulatory T cells and Th9-like cells, may reflect Treg plasticity and IL-9 axis activation in active neurodegeneration, warranting functional validation. These signatures should not be regarded as candidate biomarkers for early AD detection.
No takes yet. Share an insight, caveat, or question.
Cabañero-Navalón et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: